{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:30:11Z","timestamp":1768512611946,"version":"3.49.0"},"posted":{"date-parts":[[2024,5,23]]},"group-title":"Cancer Biology","reference-count":50,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Targeted radionuclide therapy is based on injections of cancer-specific molecules conjugated with radioactive nuclides. Despite the specificity of this treatment, it is not devoid of side-effects limiting its use and is especially harmful for rapidly proliferating organs well perfused by blood, like bone marrow. Optimization of radioconjugates administration accounting for toxicity constraints can increase treatment efficacy. Based on our experiments on disseminated multiple myeloma mouse model treated by\n                  <jats:sup>225<\/jats:sup>\n                  Ac-DOTA-daratumumab, we developed a mathematical model which investigation highlighted the following principles for optimization of targeted radionuclide therapy. 1) Nuclide to antibody ratio importance. The density of radioconjugates on cancer cells determines the density of radiation energy deposited in them. Low labeling ratio as well as accumulation of unlabeled antibodies and antibodies attached to decay products in the bloodstream can mitigate cancer radiation damage due to excessive occupation of specific receptors by antibodies devoid of radioactive nuclides. 2) Cancer binding capacity-based dosing. The rate of binding of drug to cancer cells depends on the total number of their specific receptors, which therefore can be estimated from the pharmacokinetic curve of diagnostic radioconjugates. Injection of doses significantly exceeding cancer binding capacity should be avoided since radioconjugates remaining in the bloodstream have negligible efficacy to toxicity ratio. 3) Particle range-guided multi-dosing. The use of short-range particle emitters and high-affinity antibodies allows for robust treatment optimization via initial saturation of cancer binding capacity, enabling redistribution of further injected radioconjugates and deposited dose towards still viable cells that continue expressing specific receptors.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Mathematical modeling yields general principles for optimization of targeted radionuclide therapy in mouse models of multiple myeloma that can be extrapolated on another cancer models and on clinical setting.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.05.22.595377","type":"posted-content","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T11:15:14Z","timestamp":1716462914000},"source":"Crossref","is-referenced-by-count":0,"title":["Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-9002","authenticated-orcid":false,"given":"Maxim","family":"Kuznetsov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Adhikarla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Shively","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-159X","authenticated-orcid":false,"given":"Russell C.","family":"Rockne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"2","key":"2024052508450813000_2024.05.22.595377v1.1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","year":"2023","journal-title":"Nature Cancer"},{"key":"2024052508450813000_2024.05.22.595377v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31012-1"},{"key":"2024052508450813000_2024.05.22.595377v1.3","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715572295"},{"key":"2024052508450813000_2024.05.22.595377v1.4","doi-asserted-by":"crossref","unstructured":"Danai Dima , Joshua Dower , Raymond L Comenzo , and Cindy Varga . Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer management and research, pages 7891\u20137903, 2020.","DOI":"10.2147\/CMAR.S212526"},{"issue":"1","key":"2024052508450813000_2024.05.22.595377v1.5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","year":"2020","journal-title":"Cells"},{"key":"2024052508450813000_2024.05.22.595377v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0810-4"},{"key":"2024052508450813000_2024.05.22.595377v1.7","doi-asserted-by":"crossref","unstructured":"Kilian E Salerno , Soumyajit Roy , Cathy Ribaudo , Teresa Fisher , Ravi B Patel , Esther Mena , and Freddy E Escorcia . A primer on radiopharmaceutical therapy. International Journal of Radiation Oncology* Biology* Physics, 2022.","DOI":"10.1016\/j.ijrobp.2022.08.010"},{"key":"2024052508450813000_2024.05.22.595377v1.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262751"},{"key":"2024052508450813000_2024.05.22.595377v1.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2024052508450813000_2024.05.22.595377v1.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251983"},{"key":"2024052508450813000_2024.05.22.595377v1.11","first-page":"4427","article-title":"Actinium labeled daratumumab demonstrates enhanced killing of multiple myeloma cells over naked daratumumab","volume":"130","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2024052508450813000_2024.05.22.595377v1.12","doi-asserted-by":"crossref","first-page":"1607673","DOI":"10.1080\/2162402X.2019.1607673","article-title":"Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors","volume":"8","year":"2019","journal-title":"Oncoimmunology"},{"key":"2024052508450813000_2024.05.22.595377v1.13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002603"},{"key":"2024052508450813000_2024.05.22.595377v1.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plrev.2021.10.001","article-title":"Improving cancer treatments via dynamical biophysical models","volume":"39","year":"2021","journal-title":"Physics of life reviews"},{"key":"2024052508450813000_2024.05.22.595377v1.15","doi-asserted-by":"crossref","unstructured":"Simon Ars\u00e8ne , Yves Par\u00e8s , Eliott Tixier , Sol\u00e8ne Granjeon-Noriot , Bastien Martin , Lara Bruezi\u00e8re , et al. In silico clinical trials: Is it possible? In High Performance Computing for Drug Discovery and Biomedicine, pages 51\u201399. Springer, 2023.","DOI":"10.1007\/978-1-0716-3449-3_4"},{"issue":"10","key":"2024052508450813000_2024.05.22.595377v1.16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s44222-023-00089-7","article-title":"Computational approaches to modelling and optimizing cancer treatment","volume":"1","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"key":"2024052508450813000_2024.05.22.595377v1.17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fphar.2020.00997","article-title":"Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges","volume":"11","year":"2020","journal-title":"Frontiers in pharmacology"},{"key":"2024052508450813000_2024.05.22.595377v1.18","doi-asserted-by":"publisher","DOI":"10.2307\/3579648"},{"issue":"9","key":"2024052508450813000_2024.05.22.595377v1.19","doi-asserted-by":"crossref","first-page":"e0162303","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"2024052508450813000_2024.05.22.595377v1.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.164699"},{"key":"2024052508450813000_2024.05.22.595377v1.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210377"},{"issue":"12","key":"2024052508450813000_2024.05.22.595377v1.22","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/pharmaceutics13122132","article-title":"A physio-logically based pharmacokinetic model for in vivo alpha particle generators targeting neuroendocrine tumors in mice","volume":"13","year":"2021","journal-title":"Pharmaceutics"},{"issue":"24","key":"2024052508450813000_2024.05.22.595377v1.23","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.3390\/ijms232415966","article-title":"Mathematical model for evaluation of tumor response in targeted radionuclide therapy with 211At using implanted mouse tumor","volume":"23","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"2024052508450813000_2024.05.22.595377v1.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2553"},{"issue":"20","key":"2024052508450813000_2024.05.22.595377v1.25","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.3390\/cancers13205171","article-title":"A mathematical modeling approach for targeted radionuclide and chimeric antigen receptor T cell combination therapy","volume":"13","year":"2021","journal-title":"Cancers"},{"key":"2024052508450813000_2024.05.22.595377v1.26","first-page":"1358478","article-title":"Designing combination therapies for cancer treatment: Application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy","volume":"15","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"2024052508450813000_2024.05.22.595377v1.27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","year":"2011","journal-title":"Current radiopharmaceuticals"},{"issue":"6","key":"2024052508450813000_2024.05.22.595377v1.28","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2009-2336","article-title":"Bone acquisition in healthy young females is reciprocally related to marrow adiposity","volume":"95","year":"2010","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2024052508450813000_2024.05.22.595377v1.29","doi-asserted-by":"crossref","unstructured":"Michael C Joiner and Albert J van der Kogel . Basic clinical radiobiology. CRC press, 2018.","DOI":"10.1201\/9780429490606"},{"key":"2024052508450813000_2024.05.22.595377v1.30","doi-asserted-by":"crossref","first-page":"111371","DOI":"10.1016\/j.jtbi.2022.111371","article-title":"Optimization of antitumor radiotherapy fractionation via mathematical modeling with account of 4 R\u2019s of radiobiology","volume":"558","year":"2023","journal-title":"Journal of Theoretical Biology"},{"key":"2024052508450813000_2024.05.22.595377v1.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186338"},{"issue":"10","key":"2024052508450813000_2024.05.22.595377v1.32","doi-asserted-by":"crossref","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","year":"2018","journal-title":"Oncoimmunology"},{"key":"2024052508450813000_2024.05.22.595377v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702087"},{"key":"2024052508450813000_2024.05.22.595377v1.34","first-page":"358","volume-title":"In Seminars in nuclear medicine","volume":"38","year":"2008"},{"key":"2024052508450813000_2024.05.22.595377v1.35","first-page":"1","article-title":"EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: Impact on safety and imaging quality","volume":"6","year":"2021","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"2024052508450813000_2024.05.22.595377v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.09.008"},{"issue":"11","key":"2024052508450813000_2024.05.22.595377v1.37","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/trf.17137","article-title":"Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","year":"2022","journal-title":"Transfusion"},{"key":"2024052508450813000_2024.05.22.595377v1.38","first-page":"770","volume-title":"In MAbs","volume":"7","year":"2015"},{"issue":"1","key":"2024052508450813000_2024.05.22.595377v1.39","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","year":"2022","journal-title":"Nature communications"},{"issue":"3","key":"2024052508450813000_2024.05.22.595377v1.40","first-page":"272","article-title":"The morphology of myeloma cells changes with the progression of the disease","volume":"17","year":"2013","journal-title":"Contemporary Oncology\/Wsp\u00f3lczesna Onkologia"},{"issue":"1","key":"2024052508450813000_2024.05.22.595377v1.41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2024052508450813000_2024.05.22.595377v1.42","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1007\/s10238-023-01124-y","article-title":"Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs","volume":"23","year":"2023","journal-title":"Clinical and Experimental Medicine"},{"issue":"18","key":"2024052508450813000_2024.05.22.595377v1.43","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024052508450813000_2024.05.22.595377v1.44","first-page":"486","article-title":"Pursuing the curative blueprint for early myeloma","volume":"122","year":"2013","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"2024052508450813000_2024.05.22.595377v1.45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169235"},{"key":"2024052508450813000_2024.05.22.595377v1.46","unstructured":"Marco Meglio . FDA approves subcutaneous efgartigimod as treatment for generalized myasthenia gravis. Neurology Live, 2023."},{"issue":"2","key":"2024052508450813000_2024.05.22.595377v1.47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/0008-5472.622.65.2","article-title":"Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti\u2013 carcinoembryonic antigen single-chain Fv-Fc antibody fragments","volume":"65","year":"2005","journal-title":"Cancer research"},{"key":"2024052508450813000_2024.05.22.595377v1.48","doi-asserted-by":"crossref","unstructured":"Bruna Scheuher , Khem Raj Ghusinga , Kimiko McGirr , Maksymilian Nowak , Sheetal Panday , Joshua Apgar , et al. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). Journal of Pharmacokinetics and Pharmacodynamics, pages 1\u201319, 2023.","DOI":"10.1007\/s10928-023-09884-6"},{"key":"2024052508450813000_2024.05.22.595377v1.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243394"},{"key":"2024052508450813000_2024.05.22.595377v1.50","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-019-04673-1","article-title":"The radiosensitizer onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts","volume":"47","year":"2020","journal-title":"European journal of nuclear medicine and molecular imaging"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.05.22.595377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:28:13Z","timestamp":1768458493000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.05.22.595377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1101\/2024.05.22.595377","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1158\/2767-9764.CRC-24-0306","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,5,23]]},"subtype":"preprint"}}